nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.06.2011 | Review

Clinical significance of sentinel lymph node isolated tumour cells in breast cancer

verfasst von: Neill Patani, Kefah Mokbel

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The advent of sentinel lymph node biopsy (SLNB) and improvements in histopathological and molecular analysis have increased the rate at which isolated tumour cells (ITC) are identified. However, their biological and clinical significance has been the subject of much debate. In this article we review the literature concerning SLNB with particular reference to ITC. The controversies regarding histopathological assessment, clinical relevance and management implications are explored. The literature review was facilitated by Medline, PubMed, Embase and Cochrane databases. Published studies have reported divergent results regarding the biological significance and clinical implications of ITC in general and SLN ITC in particular. Some studies demonstrate no associations, whilst others have found these to be indicators of poor prognosis, associated with non-SLN involvement, in addition to local recurrence and distant disease. Absolute consensus regarding the optimal analytical technique for SLN has yet to be reached, particularly concerning immunohistochemical (IHC) techniques targeting cytokeratins and contemporary molecular analysis. The clinical relevance of ITC within the SLN should be primarily determined by the magnitude of their impact on patient management and outcome measures. The modest up-staging within current classification systems is justified and reflects the marginally poorer prognosis for women with SLN ITC. Management need not be altered where further axillary treatment with surgical clearance or radiotherapy and systemic adjuvant treatment are already indicated. However, in the absence of level-1 guidance, each case requires discussion with regard to other tumour and patient related factors in the context of the multidisciplinary team. The identification of ITC remains highly dependent on the analytical technique employed and there exists potential for stage migration and impact on management decisions. Evidence supporting the routine analysis of deeper tissue sections by IHC is lacking and molecular technologies should be restricted to research purposes at present.

Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187PubMedCrossRef

Veronesi U, Paganelli G, Viale G (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553PubMedCrossRef

Chen SL, Hoehne FM, Giuliano AE (2007) The prognostic significance of micrometastasis in breast cancer: a SEER population-based analysis. Ann Surg Oncol 14:3378–3384PubMedCrossRef

International Agency for Research on Cancer (IARC) (2003) WHO histological classification of tumours of the breast. World Health Organization classification of tumours. In: Tavassoli FA, Devilee P (eds) Pathology and genetics, tumours of the breast and female genital organs. IARC Press, Lyon, pp 10–12

Greene FL, Page DL, Fleming ID, Fritz A, Balch CM et al (eds) (2002) AJCC cancer staging manual, 6th edn

Greene FL, Page DL, Fleming ID et al (eds) (2002) AJCC cancer staging handbook—TNM classification of malignant tumors, 6th edn. Springer Verlag, New York

Sobin LH, Wittekind C (eds) (2002) UICC TNM classification of malignant tumours, 6th edn. Wiley, New York

Cserni C, Amendoeira I, Apostolikas N et al (2003) Pathologic work-up of sentinel lymph nodes in breast cancer: review of current data to be considered for the formulation of guidelines. Eur J Cancer 39:1654–1667PubMedCrossRef

Weaver DL (2003) Sentinel lymph nodes and breast carcinoma: which micrometastases are clinically significant? Am J Surg Pathol 27:842–845PubMedCrossRef

10.

Mittendorf EA, Hunt KK (2007) Significance and management of micrometastases in patients with breast cancer. Expert Rev Anticancer Ther 7(10):1451–1461PubMedCrossRef

11.

Smeets A, Christiaens MR (2005) Implications of the sentinel lymph node procedure for local and systemic adjuvant treatment. Curr Opin Oncol 17:539–544PubMedCrossRef

12.

Schwartz GF, Giuliano AE, Veronesi U (2002) Consensus conference committee. In: Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer 94:2542–2551

13.

Lyman GH, Giuliano AE, Somerfield MR et al (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early breast cancer. J Clin Oncol 23:7703–7720PubMedCrossRef

14.

Khalifa K, Pereira B, Thomas VA, Mokbel K (2004) The accuracy of intraoperative frozen section analysis of the sentinel lymph nodes during breast cancer surgery. Int J Fertil Womens Med 49(5):208–211PubMed

15.

Tew K, Irwig L, Matthews A, Crowe P, Macaskill P (2005) Meta-analysis of sentinel node imprint cytology in breast cancer. Br J Surg 92(9):1068–1080PubMedCrossRef

16.

Schoenfeld A, Luqmani Y, Smith D, O’Reilly S, Shousha S, Sinnett HD, Coombes RC (1994) Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 154(11):2986–2990

17.

Kurosumi M, Takei H (2007) Significance and problems of histopathological examination and utility of real-time reverse transcriptase-polymerase chain reaction method for the detection of sentinel lymph node metastasis in breast cancer. Breast Cancer 14(4):342–349PubMedCrossRef

18.

Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T et al (2007) One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 13(16):4807–4816PubMedCrossRef

19.

Ishikawa T, Miyajima E, Sasaki T, Tanabe M et al (2007) Transcription-reverse transcription concerted reaction and minimal residual disease in axillary sentinel nodes of breast cancer. Eur J Surg Oncol 33(4):430–434PubMedCrossRef

20.

Treseler P (2006) Pathologic examination of the sentinel lymph node: what is the best method? Breast J 12(5 Suppl 2):S143–S151PubMedCrossRef

21.

Carter B, Jensen R, Simpson J et al (2000) Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol 113:259–265PubMedCrossRef

22.

Cserni G, Bianchi S, Boecker W et al (2005) Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer 103:358–367PubMedCrossRef

23.

Cserni G (2006) Further axillary metastases associated with isolated tumor cells in sentinel lymph nodes of breast cancer patients. Ann Surg 243:287 [author reply 287]PubMedCrossRef

24.

Cserni G, Sapino A, Decker T (2006) Discriminating between micrometastases and isolated tumor cells in a regional and institutional setting. Breast 15:347–354PubMedCrossRef

25.

Li J, Rudas M, Kemmner W, Warnick P, Fischer J, Gnant M, Schlag PM, Bembenek A (2008) The location of small tumor deposits in the SLN predicts non-SLN macrometastases in breast cancer patients. Eur J Surg Oncol 34(8):857–862PubMed

26.

Cserni G, Amendoeira I, Apostolikas N et al (2004) Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol 57:695–701PubMedCrossRef

27.

Turner RR, Weaver DL, Cserni G, Lester SC, Hirsch K, Elashoff DA, Fitzgibbons PL, Viale G, Mazzarol G, Ibarra JA, Schnitt SJ, Giuliano AE (2008) Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. J Clin Oncol 26(2):258–263PubMedCrossRef

28.

Rydén L, Chebil G, Sjöström L, Pawlowski R, Jönsson PE (2007) Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN biopsy. Eur J Surg Oncol 33(1):33–38PubMed

29.

Viale G, Maiorano E, Pruneri G et al (2005) Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg 241:319–325PubMedCrossRef

30.

Van Zee KJ, Manasseh DM, Bevilacqua JL et al (2003) A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10:1140–1151PubMedCrossRef

31.

Cserni G (2004) A model for determining the optimum histology of sentinel lymph nodes in breast cancer. J Clin Pathol 57(5):467–471PubMedCrossRef

32.

Dowlatshahi K, Fan M, Snider HC, Habib FA (1997) Lymph node micrometastases from breast carcinoma. Reviewing the dilemma. Cancer 80:1188–1197PubMedCrossRef

33.

Dowlatshanhi K, Fan M, Anderson JM, Bloom KJ (2001) Occult metastases in sentinel nodes of 200 patients with operable breast cancer. Ann Surg Oncol 8:675–681CrossRef

34.

Cote R, Peterson H, Chaiwun B et al (1999) Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet 354:896–900PubMedCrossRef

35.

Rivera M, Merlin S, Hoda R et al (2004) Minimal involvement of sentinel lymph node in breast carcinoma: prevailing concepts and challenging problems. Int J Surg Pathol 12:301–306PubMedCrossRef

36.

Mori M, Mimori K, Inoue H et al (1995) Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 55:3417–3420PubMed

37.

Leers MP, Schoffelen RH, Hoop JG et al (2002) Multiparameter flow cytometry as a tool for the detection of micrometastatic tumour cells in the sentinel lymph node procedure of patients with breast cancer. J Clin Pathol 55(5):359–366PubMedCrossRef

38.

Mesker WE, Torrenga H, Sloos WC et al (2004) Supervised automated microscopy increases sensitivity and efficiency of detection of sentinel node micrometastases in patients with breast cancer. J Clin Pathol 57(9):960–964PubMedCrossRef

39.

Weaver DL, Krag DN, Manna EA, Ashikaga T, Harlow SP, Bauer KD (2003) Comparison of pathologist-detected and automated computer-assisted image analysis detected sentinel lymph node micrometastases in breast cancer. Mod Pathol 16(11):1159–1163PubMedCrossRef

40.

Cserni G, Bianchi S, Vezzosi V, van Diest P, van Deurzen C, Sejben I, Regitnig P, Asslaber M, Foschini MP, Sapino A, Castellano I, Callagy G, Arkoumani E, Kulka J, Wells CA (2008) Variations in sentinel node isolated tumour cells/micrometastasis and non-sentinel node involvement rates according to different interpretations of the TNM definitions. Eur J Cancer 44(15):2185–2191PubMedCrossRef

41.

Cserni G (2009) Isolated tumour cells versus micrometastases and non-sentinel node involvement in breast cancer. Eur J Surg Oncol 35(8):897–898PubMed

42.

Rutgers EJ (2004) Sentinel node micrometastasis in breast cancer. Br J Surg 91(10):1241–1242PubMedCrossRef

43.

Broekhuizen LN, Wijsman JH, Peterse JL, Rutgers EJ (2006) The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. Eur J Surg Oncol 32(5):502–506PubMedCrossRef

44.

Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE (1999) Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 229(4):536–541PubMedCrossRef

45.

Imoto S, Ochiai A, Okumura C, Wada N, Hasebe T (2006) Impact of isolated tumor cells in sentinel lymph nodes detected by immunohistochemical staining. Eur J Surg Oncol 32(10):1175–1179 [Epub 2006 Sep 15]PubMedCrossRef

46.

Calhoun KE, Hansen NM, Turner RR, Giuliano AE (2005) Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection. Am J Surg 190:588–591PubMedCrossRef

47.

Pugliese MS, Beatty JD, Tickman RJ, Allison KH, Atwood MK, Szymonifka J, Arthurs ZM, Huynh PP, Dawson JH (2009) Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories. Ann Surg Oncol 16(1):113–120PubMedCrossRef

48.

Guenther JM, Hansen NM, DiFronzo LA, Giuliano AE, Collins JC, Grube BL et al (2003) Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg 138:52–56PubMedCrossRef

49.

Hansen NM, Ye X, Grube BJ, Giuliano AE (2004) Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer. Arch Surg 139:634–640PubMedCrossRef

50.

Tjan-Heijen VCG, Bult P, de Widt-Levert LM, Ruers TJ, Beex LVAM (2001) Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure. Breast Cancer Res Treat 70:81–88CrossRef

51.

Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, Julian TB, Mamounas EP, Wolmark N (2011) Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 364(5):412–421PubMedCrossRef

52.

den Bakker MA, van Weeszenberg A, de Kanter AY, Beverdam FH, Pritchard C, van der Kwast TH, Menke-Pluymers M (2002) Non-sentinel lymph node involvement in patients with breast cancer and sentinel node micrometastasis; too early to abandon axillary clearance. J Clin Pathol 55(12):932–935CrossRef

53.

van Deurzen CH, de Boer M, Monninkhof EM, Bult P, van der Wall E, Tjan-Heijnen VC, van Diest PJ (2008) Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node. J Natl Cancer Inst 100(22):1574–1580PubMedCrossRef

54.

Cserni G, Gregori D, Merletti F et al (2004) Non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer: metaanalysis of 25 studies. Br J Surg 91:1245–1252PubMedCrossRef

55.

Houvenaeghel G, Nos C, Mignotte H et al (2006) Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement—Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer. J Clin Oncol 24:1814–1822PubMedCrossRef

56.

Viale G, Maiorano E, Mazzarol G, Zurrida S, Galimberti V, Luini A et al (2001) Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 92:1378–1384PubMedCrossRef

57.

Houvenaeghel G, Nos C, Giard S, Mignotte H, Esterni B, Jacquemier J, Buttarelli M, Classe JM, Cohen M, Rouanet P, Penault Llorca F, Bonnier P, Marchal F, Garbay JR, Fraisse J, Martel P, Fondrinier E, Tunon de Lara C, Rodier JF (2009) A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol 35(7):690–695PubMed

58.

Schrenk P, Konstantiniuk P, Wolfl S, Bogner S, Haid A, Nemes C, Jagoutz-Herzlinger M, Redtenbacher S (2005) Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node. Br J Surg 92(6):707–713PubMedCrossRef

59.

Leidenius MH, Vironen JH, Heikkilä PS, Joensuu H (2010) Influence of isolated tumor cells in sentinel nodes on outcome in small, node-negative (pT1N0M0) breast cancer. Ann Surg Oncol 17(1):254–262 [Epub 2009 Oct 9]PubMedCrossRef

60.

de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, Nortier JW, Rutgers EJ, Seynaeve C, Menke-Pluymers MB, Bult P, Tjan-Heijnen VC (2009) Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361(7):653–663PubMedCrossRef

61.

Querzoli P, Pedriali M, Rinaldi R, Lombardi AR, Biganzoli E, Boracchi P, Ferretti S, Frasson C, Zanella C, Ghisellini S, Ambrogi F, Antolini L, Piantelli M, Iacobelli S, Marubini E, Alberti S, Nenci I (2006) Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res 12(22):6696–6701PubMedCrossRef

62.

Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, Hudis C, Borgen PI, Cody HS 3rd (2008) Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol 26(11):1803–1809PubMedCrossRef

63.

Cox CE, Kiluk JV, Riker AI et al (2008) Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg 206(2):261–268PubMedCrossRef

64.

Di Tommaso L, Arizzi C, Rahal D, Destro A et al (2006) Anatomic location of breast cancer micrometastasis in sentinel lymph node predicts axillary status. Ann Surg 243(5):706–707 [author reply 706–707]PubMedCrossRef

65.

Dabbs DJ, Fung M, Landsittel D, McManus K, Johnson R (2004) Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J 10(2):101–105PubMedCrossRef

66.

McCready DR, Yong WS, Ng AKT et al (2004) Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and falsenegative rates. J Natl Cancer Inst 96:873–875PubMedCrossRef

67.

Changsri C, Prakash S, Sandweiss L et al (2004) Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery. Breast J 10:392–397PubMedCrossRef

68.

Bland CS (1981) The Halsted mastectomy: present illness and past history. West J Med 134(6):549–555PubMed

69.

Fisher B, Gebhardt MC (1978) The evolution of breast cancer surgery: past, present, and future. Semin Oncol 5:385–394PubMed

70.

Fisher ER, Palekar A, Rockette H, Redmond C, Fisher B (1978) Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). V. Significance of axillary nodal micro- and macrometastases. Cancer 42(4):2032–2038 [No abstract available]PubMedCrossRef

71.

Louis-Sylvestre C, Clough K, Asselain B et al (2004) Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol 22:97–101PubMedCrossRef

72.

Singletary S, Greene G, Sobin L (2003) Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer 98:2740–2741PubMedCrossRef

73.

Singletary SE, Allred C, Ashley P et al (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20(17):3628–3636PubMedCrossRef

74.

Reynolds C, Mick R, Donohue JH et al (1999) Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 17:1720–1726PubMed

75.

Turner RR, Chu KU, Qi K, Botnick LE, Hansen NM, Glass EC et al (2000) Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 89:574–581PubMedCrossRef

76.

Weiser MR, Montgomery LL, Tan LK, Susnik B, Leung DYH, Borgen PI, Cody HS III (2000) Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol 8(2):145–149CrossRef

77.

Rahusen FD, Torrenga H, van Diest PJ, Pijpers R, van der Wall E, Licht J, Meijer S (2001) Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer. Arch Surg 136(9):1059–1063PubMedCrossRef

78.

Cserni G (2007) What is a positive sentinel lymph node in breast cancer patients? A practical approach. Breast 16:152–160PubMedCrossRef

79.

Hermanek P, Hutter RV, Sobin LH, Wittekind C (1999) Internatinternonal union against cancer. Classification of isolated tumor cells and micrometastasis. Cancer 86(12):2668–2673PubMedCrossRef

80.

Amin BD, Hoda SA (2006) Minimal metastatic disease in sentinel lymph nodes in breast carcinoma: some modest proposals to refine criteria for “isolated tumor cells”. Adv Anat Pathol 13(4):185–189PubMedCrossRef

81.

Alix-Panabieres C, Muller V, Pantel K (2007) Current status in human breast cancer micrometastasis. Curr Opin Oncol 19(6):558–563PubMedCrossRef

82.

Braun S, Vogl FD, Naume B, Janni W et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802PubMedCrossRef

83.

Wiedswang G, Naess AB, Naume B, Karesen R (2001) Micrometastasis to axillary lymph nodes and bone marrow in breast cancer patients. Breast 10(3):237–242PubMedCrossRef

84.

Cote R, Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt K (2010) ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. J Clin Oncol 28:CRA504

85.

Giuliano AE, McCall LM, Beitsch PD, Whitworth PW, Morrow M, Blumencranz PW, Leitch AM, Saha S, Hunt K, Ballman KV (2010) ACOSOG Z0011: a randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol 28:CRA506CrossRef

Titel: Clinical significance of sentinel lymph node isolated tumour cells in breast cancer
verfasst von: Neill Patani
Kefah Mokbel
Publikationsdatum: 01.06.2011
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1476-4

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Clinical significance of sentinel lymph node isolated tumour cells in breast cancer

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

PALB2 analysis in BRCA2-like families

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer

Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer

Green tea consumption and breast cancer risk: three recent meta-analyses

Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie